The Pathogenesis and Treatment of Obsessive-Compulsive Disorder
DOI:
https://doi.org/10.61173/22ces807Keywords:
Obsessive-compulsive disorder, cognitive behavioral therapy, pathogenesis and treatmentAbstract
Obsessive-compulsive disorder (OCD) is a common, chronic, severe psychiatric disorder in which people have persistent and unwanted thoughts and rigid behaviors. The main treatments for OCD include cognitive behavioral therapy (CBT) and selective serotonin reuptake inhibitors (SSRIs) but the results are not significant and very few people achieve complete remission. The cortico-striato-thalamo-cortical (CSTC) circuit is widely considered to be the neuroanatomical substrate of OCD. Based on genetic research, this circuit is operation is significantly influenced by genes that regulate the glutamatergic, dopaminergic, and serotonergic systems as well as their interactions. However, the inability to pinpoint the precise pathophysiology behind this intricate and varied condition has impeded attempts to create novel treatments or improve those that already exist. This review focuses on the pathogenesis and contributing factors associated with research aimed at elucidating the pathophysiology of OCD and advancing therapeutic interventions. By studying the neurobiological basis of OCD, including neural circuits, neurotransmitter system and genetic factors, people can understand the pathogenesis of OCD deeply, and provide a scientific basis for formulating more effective therapeutic strategies.
References
[1] American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Washington, DC: American Psychiatric Association, 2013.
[2] Ruscio A. M., Stein D. J., Chiu W. T., et al. The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. Molecular Psychiatry, 2010, 15: 53–63.
[3] Cervin M., do Rosário M. C., Fontenelle L. F., et al. Taboo obsessions and their association with suicidality in obsessivecompulsive disorder. Journal of Psychiatric Research, 2022, 154: 117-122.
[4] Fernandez T. V., Leckman J. F., Pittenger C. Genetic susceptibility in obsessive-compulsive disorder. Handbook of Clinical Neurology, 2018, 148: 767–781.
[5] Lin G. N., Song W., Wang W., et al. De novo mutations identified by whole-genome sequencing implicate chromatin modifications in obsessive-compulsive disorder. Science Advances, 2022, 8(2): eabi6180.
[6] Pauls D., Abramovitch A., Rauch S., et al. Obsessive– compulsive disorder: an integrative genetic and neurobiological perspective. Nature Reviews Neuroscience, 2014, 15: 410–424.
[7] Koran L. M., Hanna G. L., Hollander E., et al. Practice guideline for the treatment of patients with obsessive-compulsive disorder. American Journal of Psychiatry, 2007, 164(Suppl): 5.
[8] Pigott T. A., Seay S. M. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder. Journal of Clinical Psychiatry, 1999, 60: 101–106.
[9] Stein D. J., Costa D. L. C., Lochner C., Miguel E. C., Janardhan Reddy Y. C. J., Shavitt R. G., et al. Obsessivecompulsive disorder. Nature Reviews Disease Primers, 2019, 5: 52.
[10] Saxena S., Rauch S. L. Functional neuroimaging and the neuroanatomy of obsessive-compulsive disorder. Psychiatric Clinics of North America, 2000, 23: 563–586.
[11] Calzà J., Gürsel D. A., Schmitz-Koep B., Bremer B., Reinholz L., Berberich G., et al. Altered cortico-striatal functional connectivity during resting state in obsessivecompulsive disorder. Frontiers in Psychiatry, 2019, 10: 319.
[12] Posner J., Marsh R., Maia T. V., Peterson B. S., Gruber A., Simpson H. B. Reduced functional connectivity within the limbic cortico-striato-thalamo-cortical loop in unmedicated adults with obsessive-compulsive disorder. Human Brain Mapping, 2014, 35: 2852–2860.
[13] Williams N. R., Sudheimer K. D., Cole E. J., Varias A. D., Goldstein-Piekarski A. N., Stetz P., et al. Accelerated neuromodulation therapy for obsessive-compulsive disorder. Brain Stimulation, 2021, 14: 435–437.
[14] Biria M., Banca P., Healy M. P., et al. Cortical glutamate and GABA are related to compulsive behaviour in individuals with obsessive-compulsive disorder and healthy controls. Nature Communications, 2023, 14(1): 3324.
[15] Ahmari S. E., Rauch S. L. The prefrontal cortex and obsessive-compulsive disorder. Neuropsychopharmacology, 2022, 47: 211–224.
[16] Yin L., Han F., Wang Q. A biophysical model for dopamine modulating working memory through reward system in obsessive-compulsive disorder. Cognitive Neurodyn, 2024, 18(4): 1895-1911.
[17] Xue J., Qian D., Zhang B., et al. Midbrain dopamine neurons arbiter OCD-like behavior. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119(46): e2207545119.
[18] Noh H. J., Tang R., Flannick J., O’Dushlaine C., et al. Integrating evolutionary and regulatory information with a multispecies approach implicates genes and pathways in obsessive-compulsive disorder. Nature Communications, 2017, 8(1): 774.
[19] Hirschtritt M. E., Bloch M. H., Mathews C. A. Obsessivecompulsive disorder: advances in diagnosis and treatment. JAMA, 2017, 317: 1358–1367.
[20] Strauss A. Y., Huppert J. D., Simpson H. B., et al. What matters more? Common or specific factors in cognitive Dean&Francis Yixin Hu behavioral therapy for OCD: therapeutic alliance and expectations as predictors of treatment outcome. Behavior Research and Therapy, 2018, 105: 43–51.
[21] Del Casale A., Sorice S., Padovano A., et al. Psychopharmacological treatment of obsessive-compulsive disorder. Current Neuropharmacology, 2019, 17(8): 710-736.
[22] Goodman W. K., Storch E. A., Sheth S. A. Harmonizing the neurobiology and treatment of obsessive-compulsive disorder. American Journal of Psychiatry, 2021, 178(1): 17-29.
[23] Goodman W. K., Price L. H., Delgado P. L., et al. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: comparison of fluvoxamine and desipramine. Archives of General Psychiatry, 1990, 47: 577– 585.
[24] Goodman W. K., McDougle C. J., Price L. H., et al. Beyond the serotonin hypothesis: a role for dopamine in some forms of obsessive-compulsive disorder? Journal of Clinical Psychiatry, 1990, 51(Suppl): 36–43.
[25] Carmi L., Tendler A., Bystritsky A., et al. Efficacy and safety of deep transcranial magnetic stimulation for obsessivecompulsive disorder: a prospective multicenter randomized double-blind placebo-controlled trial. American Journal of Psychiatry, 2019, 176: 931–938.
[26] McCathern A. G., Mathai D. S., Cho R. Y., Goodman W. K., Storch E. A. Deep transcranial magnetic stimulation for obsessive-compulsive disorder. Expert Review of Neurotherapeutics, 2020, 20(10): 1029-1036.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
